These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 10949938)

  • 1. p53 gene mutation and ink4a-arf deletion appear to be two mutually exclusive events in human glioblastoma.
    Fulci G; Labuhn M; Maier D; Lachat Y; Hausmann O; Hegi ME; Janzer RC; Merlo A; Van Meir EG
    Oncogene; 2000 Aug; 19(33):3816-22. PubMed ID: 10949938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The early growth response gene EGR-1 behaves as a suppressor gene that is down-regulated independent of ARF/Mdm2 but not p53 alterations in fresh human gliomas.
    Calogero A; Arcella A; De Gregorio G; Porcellini A; Mercola D; Liu C; Lombari V; Zani M; Giannini G; Gagliardi FM; Caruso R; Gulino A; Frati L; Ragona G
    Clin Cancer Res; 2001 Sep; 7(9):2788-96. PubMed ID: 11555594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic profile of gliosarcomas.
    Reis RM; Könü-Lebleblicioglu D; Lopes JM; Kleihues P; Ohgaki H
    Am J Pathol; 2000 Feb; 156(2):425-32. PubMed ID: 10666371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigation of germline PTEN, p53, p16(INK4A)/p14(ARF), and CDK4 alterations in familial glioma.
    Tachibana I; Smith JS; Sato K; Hosek SM; Kimmel DW; Jenkins RB
    Am J Med Genet; 2000 May; 92(2):136-41. PubMed ID: 10797439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preferential inactivation of the p53 tumor suppressor pathway and lack of EGFR amplification distinguish de novo high grade pediatric astrocytomas from de novo adult astrocytomas.
    Sung T; Miller DC; Hayes RL; Alonso M; Yee H; Newcomb EW
    Brain Pathol; 2000 Apr; 10(2):249-59. PubMed ID: 10764044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inactivation of the INK4A/ARF locus frequently coexists with TP53 mutations in non-small cell lung cancer.
    Sanchez-Cespedes M; Reed AL; Buta M; Wu L; Westra WH; Herman JG; Yang SC; Jen J; Sidransky D
    Oncogene; 1999 Oct; 18(43):5843-9. PubMed ID: 10557071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines.
    Ishii N; Maier D; Merlo A; Tada M; Sawamura Y; Diserens AC; Van Meir EG
    Brain Pathol; 1999 Jul; 9(3):469-79. PubMed ID: 10416987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deregulation of the p14ARF/MDM2/p53 pathway is a prerequisite for human astrocytic gliomas with G1-S transition control gene abnormalities.
    Ichimura K; Bolin MB; Goike HM; Schmidt EE; Moshref A; Collins VP
    Cancer Res; 2000 Jan; 60(2):417-24. PubMed ID: 10667596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. INK4a/ARF locus alterations in human non-Hodgkin's lymphomas mainly occur in tumors with wild-type p53 gene.
    Pinyol M; Hernández L; Martínez A; Cobo F; Hernández S; Beà S; López-Guillermo A; Nayach I; Palacín A; Nadal A; Fernández PL; Montserrat E; Cardesa A; Campo E
    Am J Pathol; 2000 Jun; 156(6):1987-96. PubMed ID: 10854221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deregulation of the p14ARF/Mdm2/p53 pathway and G1/S transition in two glioblastoma sets.
    Ghimenti C; Fiano V; Chiadò-Piat L; Chiò A; Cavalla P; Schiffer D
    J Neurooncol; 2003 Jan; 61(2):95-102. PubMed ID: 12622447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutations of TP53, amplification of EGFR, MDM2 and CDK4, and deletions of CDKN2A in malignant astrocytomas.
    Biernat W; Debiec-Rychter M; Liberski PP
    Pol J Pathol; 1998; 49(4):267-71. PubMed ID: 10323080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of the p16INK4, p14ARF, p15, TP53, and MDM2 genes and their prognostic implications in osteosarcoma and Ewing sarcoma.
    Tsuchiya T; Sekine K; Hinohara S; Namiki T; Nobori T; Kaneko Y
    Cancer Genet Cytogenet; 2000 Jul; 120(2):91-8. PubMed ID: 10942797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence of p14ARF gene deletion in high-grade adult and pediatric astrocytomas.
    Newcomb EW; Alonso M; Sung T; Miller DC
    Hum Pathol; 2000 Jan; 31(1):115-9. PubMed ID: 10665922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. INK4a-ARF alterations and p53 mutations in hepatocellular carcinomas.
    Tannapfel A; Busse C; Weinans L; Benicke M; Katalinic A; Geissler F; Hauss J; Wittekind C
    Oncogene; 2001 Oct; 20(48):7104-9. PubMed ID: 11704835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dysfunction of p53 pathway in human colorectal cancer: analysis of p53 gene mutation and the expression of the p53-associated factors p14ARF, p33ING1, p21WAF1 and MDM2.
    Tachibana M; Kawamata H; Fujimori T; Omotehara F; Horiuchi H; Ohkura Y; Igarashi S; Kotake K; Kubota K
    Int J Oncol; 2004 Oct; 25(4):913-20. PubMed ID: 15375540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p14ARF homozygous deletion or MDM2 overexpression in Burkitt lymphoma lines carrying wild type p53.
    Lindström MS; Klangby U; Wiman KG
    Oncogene; 2001 Apr; 20(17):2171-7. PubMed ID: 11360201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutational analysis of selected genes in the TGFbeta, Wnt, pRb, and p53 pathways in primary uveal melanoma.
    Edmunds SC; Kelsell DP; Hungerford JL; Cree IA
    Invest Ophthalmol Vis Sci; 2002 Sep; 43(9):2845-51. PubMed ID: 12202501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas.
    Boström J; Meyer-Puttlitz B; Wolter M; Blaschke B; Weber RG; Lichter P; Ichimura K; Collins VP; Reifenberger G
    Am J Pathol; 2001 Aug; 159(2):661-9. PubMed ID: 11485924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alterations of p14ARF, p53, and p73 genes involved in the E2F-1-mediated apoptotic pathways in non-small cell lung carcinoma.
    Nicholson SA; Okby NT; Khan MA; Welsh JA; McMenamin MG; Travis WD; Jett JR; Tazelaar HD; Trastek V; Pairolero PC; Corn PG; Herman JG; Liotta LA; Caporaso NE; Harris CC
    Cancer Res; 2001 Jul; 61(14):5636-43. PubMed ID: 11454718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic and pathologic significance of quantitative protein expression profiling in human gliomas.
    Chakravarti A; Delaney MA; Noll E; Black PM; Loeffler JS; Muzikansky A; Dyson NJ
    Clin Cancer Res; 2001 Aug; 7(8):2387-95. PubMed ID: 11489817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.